Asthma & Chronic Cough CRO Services

Tell us about your study

We’ll connect you with the right Asthma & Cough Specialist

Managing Enrollment Complexity in Asthma & Chronic Cough

We bring together site selection built on documented enrollment history, biomarker screening infrastructure that holds eligibility consistent, and spirometry quality managed above industry benchmark, to help our partners de-risk enrollment and protect the submission.

Narrow & Dynamic Eligibility Criteria

Exacerbation history, blood eosinophil thresholds, FEV1 criteria, and concomitant medication restrictions narrow eligibility at any given point, and asthma trials running in parallel compete for the same treatment-experienced patients.

Biomarker Screening & Screen Failure Risk

Eosinophilic and severe asthma subtypes require blood eosinophil counts, FeNO testing, and other biomarker criteria that add complexity at screening and raise eligibility risk across global sites. 

Endpoint Quality Across Global Sites

Spirometry variability across sites separates a clean regulatory submission from one that requires adjudication, particularly in global programs where ATS/ERS guideline adherence is inconsistent.

Senior Respiratory Partnership Across the Life of the Program 

Sponsors have direct access to the respiratory leaders who have delivered asthma programs across dozens of countries, from protocol design through database lock. On multi-protocol programs, resourcing is assigned at program level rather than study by study, which removes duplication and holds activation timelines. 

What Worldwide’s Asthma Programs Have Delivered

14 respiratory studies over the past five years across 2,029 sites, 4,951 patients, and 42 countries, including one of the largest asthma programs run in that period. 

2,000+

Participants

995

Sites

31

Countries

94%

Acceptable PFT Quality

14

Respiratory Studies

42

Countries

Reduced Risk Where Eligible Patients Are Hardest to Find

Pediatric Center of Excellence 

Established pediatric research infrastructure for asthma indications, spanning regulatory, pharmacometric, and global trial delivery capability. 

Endpoint Reliability & Site Coaching

Equipment quality, data review, and ongoing site coaching integrated into every respiratory program through a strategic partnership with Clario, alongside specialized respiratory guideline training for CRAs and site staff.

Site Networks Built on Enrollment History

Established site relationships across North America, Latin America, Europe, and Asia-Pacific, selected on asthma enrollment history, real-world treatment access and data quality rather than legacy lists.

Your Questions Answered

We have answered the questions sponsors ask most often about asthma and chronic cough programs. If yours isn’t here, our respiratory team is happy to help.

Sites are selected on documented enrollment history, real-world treatment access, and established investigator relationships rather than legacy site lists, prioritizing geographies where eligible patients are active and reachable.

Our spirometry quality runs at 94% acceptable against a 91% industry benchmark, with CRA and medical expert training aligned to ATS/ERS 2019 standards and continuous data monitoring across all sites.

Yes. Worldwide has managed asthma programs requiring blood eosinophil counts, FeNO testing and other biomarker screening criteria across Phase I-IV, with site infrastructure and training built around biomarker-dependent eligibility.

Yes. Worldwide supports both through an established center of excellence in pediatric clinical research, with integrated regulatory, pharmacometric and global trial delivery capability.

On a four-study global asthma program across Asia Pacific, Europe, Latin America, and North America, resourcing was assigned at program level rather than protocol by protocol, removing duplication of effort and accelerating internal reviews. Subject matter experts developed specialized respiratory guideline training for CRAs and site staff, which reduced protocol deviations and sped activation. The program enrolled 2,000+ participants across 995 sites in 31 countries, with 170 sites activated in under 90 days and 67% retention into the extension study.